---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-051361"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:41:45.117858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial

## Summary
- Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.
- Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.
- Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.
- CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103.

## SEC filing metadata
- accession: 0001213900-25-051361
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/0001213900-25-051361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/ea0244733-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-051361
- JSON: https://secwatch.observer/filing/0001213900-25-051361.json
- Plain text: https://secwatch.observer/filing/0001213900-25-051361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.